Breaking Finance News

Barclays upgraded Sanofi (NYSE:SNY) from Underweight to Equal Weight in a report released today.

Barclays has upgraded Sanofi (NYSE:SNY) from Underweight to Equal Weight in a statement released on 11/15/2017.

Displaying a price of $47.28, Sanofi (NYSE:SNY) traded -0.02% lower on the day. The last stock close price is down -1.80% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the date range. Sanofi has recorded a 50-day average of $49.49 and a two hundred day average of $48.40. Trade Volume was up over the average, with 2,367,326 shares of SNY changing hands over the typical 1,080,140

Recent Performance Chart

Sanofi (NYSE:SNY)

Sanofi has PE ratio of 11.04 with a one year low of $37.25 and a one year high of $50.65 and has a market capitalization of $0.

A total of 3 equity analysts have released a research note on the stock. 1 broker rating the company a strong buy, zero brokerages rating the company a buy, two brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally zero analysts rating the company a sell with a one year target price of $52.00.

About Sanofi (NYSE:SNY)

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.